SCHEMBL982298

SCHEMBL982298

CC(C)(C)OC(=O)n1c(C#N)cc2cc(C3(Cc4ccccc4)CCN(Cc4ccccc4)C3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
NR1H2 P55055 5/20 0.38
KDM4E B2RXH2 1/20 0.38
KMT2A Q03164 1/20 0.38
NR1H3 Q13133 2/20 0.37
NPFFR1 Q9GZQ6 1/20 0.36
NPFFR2 Q9Y5X5 1/20 0.36
TACR1 P25103 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
NR3C1 P04150 2/20 0.36
CYP3A4 P08684 3/20 0.35
TSHR P16473 3/20 0.35
CYP2D6 P10635 2/20 0.35
USP2 O75604 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2798825 0.98 PDE4A (0.38) PDE4APDE4BPDE4CPDE4DJAK2
SCHEMBL980937 0.84 SLC6A2 (0.52) NR1H2NR1H3CYP2D6
SCHEMBL980851 0.84 MAOA (0.43) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL982934 0.82 CYP2D6 (0.42) PDE4APDE4BPDE4CPDE4DJAK2
SCHEMBL12923045 0.79 KDM4E (0.41) KDM4EKMT2ANR3C1CYP3A4TSHR
SCHEMBL19687739 0.77 RORC (0.46) KMT2ACYP3A4TSHRCYP2D6USP2
SCHEMBL19687703 0.77 CYP3A4 (0.43) NR1H2KMT2ANR1H3CYP3A4TSHR
SCHEMBL16030138 0.72 NR1H2 (0.47) NR1H2NR1H3
SCHEMBL5677101 0.71 NR1H2 (0.59) NR1H2NR1H3
SCHEMBL16090764 0.71 NR1H2 (0.48) NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 PDE4A 109/4885PDE4B 111/4885PDE4C 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.